- Home
- HGLB vs CGEN Comparison
HGLB vs CGEN Comparison
Compare HGLB & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HGLB | CGEN |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.3M | 201.8M |
| IPO Year | 2015 | 2001 |
Fundamental Metrics
Financial Performance| Metric | HGLB | CGEN |
|---|---|---|
| Price | $6.53 | $1.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 114.6K | ★ 169.3K |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.32 | $1.43 |
| 52 Week High | $10.64 | $3.24 |
Technical Indicators
Market Signals| Indicator | HGLB | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 29.61 |
| Support Level | $6.50 | $1.58 |
| Resistance Level | $7.67 | $2.37 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 51.19 | 3.09 |
Price Performance
Historical ComparisonAbout HGLB Highland Global Allocation Fund
Highland Global Allocation Fund is a diversified, closed-end management investment company. The investment objective of the Fund is to seek long-term growth of capital and future income. The Fund seeks to achieve its investment objectives by investing in a portfolio of U.S. and foreign equity, debt, and money market securities. It may also invest in senior loans to domestic or foreign corporations, partnerships, and other entities that operate in a variety of industries and geographic regions.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.